Diagnostic labs partnerships – India’s next IVD growth frontier

India’s diagnostics landscape is undergoing a structural shift – one that is redefining how the in vitro diagnostics (IVD) industry engages with its customers. At the center of this transformation is the rapid rise of organized diagnostic chains and the consolidation of smaller, independent laboratories. Standalone labs that once dominated local markets are increasingly being acquired or outcompeted by large national and regional chains. These networks bring scale, standardization, and capital, but also fundamentally change the rules of engagement. Decision-making is now centralized, procurement is strategic, and expectations from partners are significantly higher.

At the same time, government initiatives such as Ayushman Bharat are expanding access to diagnostics, particularly in semi-urban and rural India. This is accelerating demand while also increasing pressure on labs to deliver high-quality testing at lower costs.

For IVD companies, traditional sales approaches, focused on individual instruments, relationships, and price negotiations, are no longer sufficient.

Large diagnostic chains now drive a significant share of volumes, operating with a sharp focus on return on investment (ROI), asset utilization, and cost per test. As they expand through acquisitions and hub-and-spoke models, they introduce pricing uniformity–but also intense price pressure. Leveraging scale, these players demand lower reagent costs, bundled offerings, long-term contracts, and standardized pricing across geographies.

The conversation has shifted from “What is the price?” to “What is the total cost of ownership and how does this improve network profitability?”

In this evolving landscape, IVD companies must transition from being vendors to becoming strategic partners. Reagent rental agreements, volume-based pricing, and bundled solutions across portfolios are no longer optional; they are expected. Chains increasingly prefer partners that can support multiple diagnostic segments within a unified commercial framework, thereby simplifying procurement and maximizing value.

In this evolving environment, Sysmex is aligning its strategy to partner closely with large diagnostic chains while continuing to support smaller laboratories, particularly in Tier-II and Tier-III markets. This dual approach recognizes both the scale of organized networks and the continued importance of decentralized healthcare delivery.

Globally, Sysmex holds a leading position in hematology, urinalysis, and hemostasis within the IVD domain, supporting the health of people in over 190 countries and regions. In India, this commitment is reinforced by the establishment of a manufacturing facility in Sanand, Gujarat – strengthening local capabilities and responsiveness to market needs. Beyond commercial models such as reagent rentals, volume-linked pricing, and bundled solutions, clinical and scientific collaboration is emerging as a key differentiator. Labs increasingly value partners who can support evidence generation, publications, and clinical credibility.

Operational efficiency is equally critical. High-volume networks require optimized workflows, minimal downtime, and strong service support, making application expertise and digital integration essential.

As the market consolidates, success will depend on a clear shift, from pricing to value, from transactions to partnerships, and from products to integrated solutions.

In a market defined by rising expectations and cost pressures, sustainable growth will come from being the most valuable partner – one that evolves alongside India’s rapidly transforming diagnostics ecosystem.